In a groundbreaking collaboration aimed at addressing the growing obesity epidemic, Eli Lilly has joined forces with retail giant Walmart to make access to its groundbreaking obesity treatment, Zepbound, more affordable for patients.
This strategic partnership not only ensures that individuals can obtain Zepbound at an unprecedented 50% savings compared to other GLP-1 obesity treatments, but it also transforms the way patients access essential medication.
By allowing patients to order Zepbound online through Lilly’s platform and conveniently pick it up at local Walmart pharmacies, this initiative is designed to empower patients paying cash without the constraints of insurance coverage.
This development is particularly timely as Eli Lilly looks to counter the emerging competition from telehealth providers who offer lower-cost alternatives.
As highlighted by recent statistics, a remarkable 35% of new Zepbound prescriptions in the second quarter of 2025 were fulfilled through this innovative direct-to-consumer channel, suggesting a significant shift in the healthcare landscape towards more patient-centric models.
In this article, we will explore the details of this partnership, its implications for patient care, and the broader impact on the healthcare system.
